Seatrack International Tradex Private Limited

Seatrack International Tradex Private Limited, established on April 20, 2019, is a private limited company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U74999DL2019PTC348869 and is classified as a non-government entity. Its authorized share capital is ₹5 million, with a paid-up capital of ₹100,000. The registered office is located at K-72-A Ground Floor, Kalkaji, New Delhi, Delhi, 110019.

The company operates in the infrastructure and utilities sector, focusing on business activities categorized under NIC code 74999, which includes other business activities not elsewhere classified. As of the latest available data, the company has two directors: Susheel Kumar and Shikha Sharma. Susheel Kumar has been serving as a director since April 20, 2019, while Shikha Sharma joined as a director on March 6, 2021.

Financially, Seatrack International Tradex Private Limited has demonstrated significant growth. In the fiscal year ending March 31, 2023, the company reported a 226.77% increase in total revenue compared to the previous year. Profitability also improved, with a 208.67% increase in profit. The net worth of the company saw a substantial rise of 276.79% during the same period.

Specific details regarding Seatrack International Tradex Private Limited's manufacturing facilities are not publicly disclosed. The company's registered address is in New Delhi, suggesting that its operations may be centralized in this location. However, without explicit information, it is challenging to provide a comprehensive overview of their manufacturing capabilities, capacities, and specializations.

The leadership team of Seatrack International Tradex Private Limited comprises two directors:

• Susheel Kumar: Serving as a director since April 20, 2019, Susheel Kumar has been instrumental in steering the company's strategic direction and operations.

• Shikha Sharma: Appointed as a director on March 6, 2021, Shikha Sharma brings additional expertise to the leadership team, contributing to the company's growth and development.

The company's leadership has been pivotal in achieving significant financial growth, including a 226.77% increase in total revenue in the fiscal year ending March 31, 2023.

Seatrack International Tradex Private Limited's export activities, as reported by TransData Nexus, indicate a focus on the Advanced Oncology therapeutic category, with a portfolio concentration of 100% in this area. The company's top five exported products include Bleomycin, Tofacitinib, Axitinib, and Regorafenib, all of which are finished pharmaceutical formulations. Notably, Axitinib holds the #1 market position with a 11.6% market share.

While specific regulatory filings and approvals in the US, EU, UK, Australia, and Japan are not detailed in the available data, the company's export activities suggest compliance with international standards. The focus on advanced oncology products indicates adherence to stringent regulatory requirements in these markets. However, without explicit information on regulatory approvals, a comprehensive analysis of the company's presence in these regulated markets cannot be provided.

Seatrack International Tradex Private Limited's export data highlights a strong presence in the Advanced Oncology therapeutic category, with a portfolio concentration of 100% in this area. The company's top five exported products, including Bleomycin, Tofacitinib, Axitinib, and Regorafenib, are finished pharmaceutical formulations, indicating a focus on delivering ready-to-use medications. Notably, Axitinib holds the #1 market position with a 11.6% market share.

While the available data does not specify the company's penetration in Africa, Latin America, and Southeast Asia, the emphasis on advanced oncology products suggests potential opportunities in emerging markets where there is a growing demand for specialized cancer treatments. The company's commitment to providing high-quality pharmaceutical products positions it well to meet the needs of these regions. However, without explicit information on WHO prequalification or other certifications, a detailed assessment of the company's access to these markets cannot be provided.

Seatrack International Tradex Private Limited's export data reveals a concentrated portfolio, with 100% of its exports in the Advanced Oncology therapeutic category. The top five exported products, including Bleomycin, Tofacitinib, Axitinib, and Regorafenib, are finished pharmaceutical formulations, indicating a strategic focus on delivering ready-to-use medications. Notably, Axitinib holds the #1 market position with a 11.6% market share.

This concentration suggests a strategic direction aimed at establishing a strong presence in the oncology market. While this focus allows for specialization and expertise in a specific therapeutic area, it also presents concentration risk. Diversifying the product portfolio could mitigate potential risks associated with market fluctuations in the oncology sector. The company's strategic direction appears to be aligned with the growing global demand for specialized cancer treatments, positioning it to leverage opportunities in both developed and emerging markets.

Specific details regarding Seatrack International Tradex Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data indicates a focus on finished pharmaceutical formulations in the Advanced Oncology therapeutic category, suggesting compliance with international standards. However, without explicit information on FDA approvals and inspections, a comprehensive assessment of the company's status with the FDA cannot be provided.

The available data does not specify whether Seatrack International Tradex Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. Given the company's focus on advanced oncology products, obtaining such certifications would be beneficial for accessing international markets. However, without explicit information on these certifications, a detailed assessment cannot be provided.

Seatrack International Tradex Private Limited operates under the regulatory oversight of the Central Drugs Standard Control Organization (CDSCO), the national regulatory authority for pharmaceuticals and medical devices in India. The company's registered address is in New Delhi, suggesting compliance with local regulatory requirements. However, specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. Without explicit information, a comprehensive assessment of the company's compliance with Indian regulatory standards cannot be provided.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts associated with Seatrack International Tradex Private Limited. The company's export data indicates a focus on finished pharmaceutical formulations in the Advanced Oncology therapeutic category, suggesting adherence to international standards. However, without explicit information on regulatory actions, a detailed assessment cannot be provided.

Seatrack International Tradex Private Limited operates in the competitive oncology pharmaceutical market, focusing on finished formulations such as Bleomycin, Tofacitinib, Axitinib, and Regorafenib. Notably, Axitinib holds the #1 market position with a 11.6% market share. The company's concentration in the Advanced Oncology therapeutic category suggests a strategic focus on this specialized market segment.

While specific competitors are not identified in the available data, the oncology pharmaceutical market is characterized by several established players with diverse product portfolios. Seatrack's emphasis on finished formulations and its market leadership in Axitinib position it as a competitive entity in this sector. However, the company's concentrated product portfolio may expose it to risks associated with market fluctuations in the oncology segment.

Seatrack International Tradex Private Limited's key differentiators include its specialized focus on the Advanced Oncology therapeutic category and its portfolio of finished pharmaceutical formulations. The company's market leadership in Axitinib, with a 11.6% market share, underscores its expertise and competitive positioning in this segment. This specialization allows the company to leverage in-depth knowledge and operational efficiencies within the oncology market.

Seatrack International Tradex Private Limited's strategic direction appears to be centered on the oncology market, with a concentrated portfolio in the Advanced Oncology therapeutic category. This focus aligns with the growing global demand for specialized cancer treatments. While the company's concentration in a single therapeutic area allows for specialization, it also presents concentration risk. Diversifying the product portfolio could mitigate potential risks associated with market fluctuations in the oncology sector. The company's emphasis on finished pharmaceutical formulations positions it to meet the needs of both developed and emerging markets.